CCL20 and chronic obstructive pulmonary disease: The number of IOD-comprising OX62+ cells was significantly increased in the COPD group compared with controls (17.07 ± 1.35 vs 73.45 ± 2.21; P < 0.001), and was significantly decreased in the CCL20 monoclonal antibody treated group compared with the COPD group (37.58 ± 1.55 vs 73.45 ± 2.21; P < 0.001) (Figure 4, Figure 5).